

Pharmacy Benefact

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS

Number 617 • June 2016

Removal of temporary benefit from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of pms-Sulfasalazine 500 mg Tablet (DIN 00598461), manufactured by Pharmascience Inc., Salazopyrin 500 mg Tablet (DIN 02064480), manufactured by Pfizer Canada Inc., was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Pharmascience Inc. has advised Alberta Blue Cross that the shortage of pms-Sulfasalazine 500 mg Tablet (DIN 00598461) has been resolved.

As a result, Salazopyrin 500 mg Tablet (DIN 02064480) will no longer be considered a temporary benefit for the *ADBL* **after July 13, 2016.**

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free)

FAX 780-498-8406 (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit <https://www.ab.bluecross.ca/providers/pharmacy-home.php>



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.617 2016/06

